## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL										
3235-0287										
Estimated average burden										
0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Semechkin Andrey					2. Issuer Name and Ticker or Trading Symbol International Stem Cell CORP [ ISCO.OB ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
ast) (First) (Mddle) O INTERNATIONAL STEM CELL CORP.						3. Date of Earliest Transaction (Month/Day/Year) 08/15/2018						Officer (give ti below)	tle Ol	her (specify low)		
5950 PRIESTLY DRIVE  (Street)  CARLSBAD CA 92008  (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year) 08/17/2018						Individual or Joint/Group Filing (Check Applicable Line)     X Formfiled by One Reporting Person     Formfiled by More than One Reporting Person						
1. Title of Security (Instr. 3) 2. Transact Date					2A. Exe if an	Deemed cution Date	e,	3. Transaction Code (Instr.	4. Securities	Acquired f (D) (Instr.	(A) or 5 3, 4 B	. Amount of ecurities eneficially wned Followi eported	Form: Dire	of Indirect Beneficia Ownersi	et al	
	1	Table I								or Bei	neficially	nstr. 3 and 4)				
	2. 3. Transaction Date Execution Date (Month/Day/Year) (Month/Day/Ye					5. Number Derivative Securities Acquired (or Dispose of (D) (Instr		e s (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Ti of S Und Deri		of Securi Underlyin Derivativ	ties ig e Security	Derivative	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
\$1.58	08/15/2018			A		150,000		(1)	08/15/2028	Common Stock	150,000	\$0	150,000	D		
T nEcric	(First ATION LY DRI  CA (State of the content of th	(First) (NATIONAL STEM CELL LY DRIVE  CA 92  (State) (Z  Table   I  rity (Instr. 3)  version xercise of vative urity  (Month/Day/Year)	(First) (Mddle) ATIONAL STEM CELL CORP LY DRIVE  CA 92008  (State) (Zip)  Table I - Non rity (Instr. 3)  Table I  version pate (Month/Day/Year) (Month/	(First) (Mddle) ATIONAL STEM CELL CORP. LY DRIVE  CA 92008  (State) (Zip)  Table I - Non-Deriva rity (Instr. 3) 2. Transac Date (Month/Day) version xercise (Month/Day/Year) version v	Table II - Derivative Sorting (Month/Day/Year)  Table II - Derivative (e.g., puts, of varive urity  Table II - Derivative (month/Day/Year)  Table II - Derivative (a.g., puts, of varive urity  Table II - Code  Table II - Derivative (a.g., puts, of varive urity)  Table II - Derivative (a.g., puts, of varive urity)  Table II - Derivative (a.g., puts, of varive urity)  Table II - Derivative (a.g., puts, of varive urity)  Table II - Derivative (a.g., puts, of varive urity)	Table II - Derivative Security (Instr. 3)  Table II - Derivative Security (Month/Day/Year)  Table II - Derivative Security (Month/Day/Year)	Table II - Derivative Securities A (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year) (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year) (Month/Day/Year)  Table II - Code (Instr. 8)  Table II - Derivative Securities (e.g., puts, calls, warra (Month/Day/Year) (Month/Day/Year)	Table II - Derivative Securities Acquestria (Month/Day/Year)  Table II - Derivative Securities Acquestria (Month/Day/Year)	International Stem Cell CORP IS 3. Date of Earliest Transaction (Month/Da) 08/15/2018  CA 92008  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired (A) Code V  Table II - Derivative Securities Acquired (B) Code (Instr. 8)  Table II - Derivative Securities Acquired (B) Code (Instr. 8)  Code V  Code V  (Month/Day/Year)  Table II - Derivative Securities Acquired (B) Code (Instr. 8)  Code V  Date Exercisable	International Stem Cell CORP [ISCO.OB]	International Stem Cell CORP [ISCO.OB]	International Stem Cell CORP [ISCO.OB]   (Check at X   X   Amount (Check at X   X   X   X   X   X   X   X   X   X	International Stem Cell CORP [ISCO.OB] (Check all applicable) X Drector X Driector X Dri	International Stem Cell CORP [ISCO.OB]  3. Date of Earliest Transaction (Month/Day/Year)  O8/15/2018  CA 92008  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Fallowing (Month/Day/Year)  Ode (mstr.)  Ode	International Stem Cell CORP   ISCO.OB     ICOneck all applicable   X Director   X 10% Owner   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive Officer   X Officer (give title   Other (specify below)   Chief Executive   Other (specify below)   Other (spec	

## Explanation of Responses:

1. 3/36th of the shares underlying such options shall vest on September 21, 2018, and the remaining share in equal monthly installments over a period of 33 months. This amendment is being filed to correct the previously reported expiration date of the stock option.

/s/ Sophia Garnette, Attorney-

in-Fact

\*\* Signature of Reporting Person

Date

09/27/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.